摘要
丙型病毒性肝炎供者器官作为一种边缘性器官已经被应用于实体器官移植中,在有效缓解器官短缺现况的同时,也面临着一些挑战,如丙型肝炎病毒(HCV)传播。但随着直接抗病毒药物的出现和应用,丙型病毒性肝炎的治愈逐渐成为现实,这也为丙型病毒性肝炎患者成为器官移植供者奠定了基础。目前,在抗病毒药物的辅助治疗下,丙型病毒性肝炎供者实体器官移植取得了一定的疗效。因此,本文总结丙型病毒性肝炎供者肾脏、心脏、肺脏及肝脏等移植的研究现状,就丙型病毒性肝炎供者在实体器官移植中的应用情况及抗病毒药物辅助治疗的安全有效性做一综述,探究丙型病毒性肝炎供者在实体器官移植中可行性,以期为扩大器官移植供体池提供参考,减少终末期疾病患者器官移植的等待时间。
As a marginal organ donor,organs from hepatitis C donors have been applied in solid organ transplantation.While effectively alleviating the shortage of organs,it also faces certain challenges,such as the spread of hepatitis C virus(HCV).With the emergence and application of direct-acting antiviral agent,the cure of hepatitis C has gradually become a reality,laying the foundation for hepatitis C patients to become organ transplant donors.At present,with adjuvant treatment using antiviral drugs,certain efficacy has been achieved in solid organ transplantation from hepatitis C donors.In this article,research progress in kidney,heart,lung and liver transplantation from hepatitis C donors,the application of hepatitis C donors in solid organ transplantation and the safety and effectiveness of antiviral drugs were reviewed,and the feasibility of hepatitis C donors in solid organ transplantation was evaluated,aiming to provide reference for expanding the donor pool of organ transplantation and shortening the waiting time for organ transplantation in patients with end-stage diseases.
作者
秦旨文
张武
Qin Zhiwen;Zhang Wu(Zhejiang Chinese Medical University,Hangzhou 310000,China)
出处
《器官移植》
CAS
CSCD
北大核心
2024年第3期390-397,共8页
Organ Transplantation
基金
国家重点研发计划(2023YFC2505900)
济南微生态生物医学省实验室科研项目资助重点项目(JNL-2022015B)。
